Shinichi Makita

26PUBLICATIONS
64CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Oncology and carcinogenesis not elsewhere classifiedHaematological tumoursTumour immunologyLiquid biopsies
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (26)

|Aug 07, 2026
Effectiveness of anti-CD19 CAR T-cell therapy for high-grade B-cell lymphoma in Japan: a single-institution analysis.

|May 20, 2026
Atezolizumab for relapsed/refractory extranodal NK/T-cell lymphoma: phase 2 of NCCH1903/ATTACK trial.

|Apr 12, 2026
Real-world outcomes of chimeric antigen receptor T-cell therapy with pembrolizumab as holding and/or bridging therapy in relapsed/refractory primary mediastinal large B-cell lymphoma.

Risa Nishiyama, Shinichi Makita, Anna Hiratsuka

|Feb 14, 2026
Disease status at CAR T-cell infusion in relapsed or refractory large B-cell lymphoma: prognostic significance for real-world outcomes, irrespective of bridging therapy.

Yu Yagi, Yusuke Kanemasa, Hideki Goto

|Jan 12, 2026
Efficacy and safety of subcutaneous mosunetuzumab in combination with lenalidomide and as a monotherapy in Japanese patients with relapsed/refractory follicular lymphoma.

Shinichi Makita, Koji Izutsu, Yuko Mishima

|Jan 08, 2026
Real-world effectiveness and safety of lisocabtagene maraleucel for relapsed/refractory large B cell lymphoma in Japan.

Tetsuro Ochi, Shinichi Makita, Anna Hiratsuka

Pageof 5

Frequent Collaborators

7 joint publications

Dai Maruyama

6 joint publications

Koji Izutsu

4 joint publications

Akiko Miyagi-Maeshima

2 joint publications

Kosuke Toyoda